Dr. Sabitha Eppanapally, MD

Dr. Eppanapally practices at Northeast Dialysis in Bakersfield, California.

Dr. Eppanapally's NPI, 1043449812, was assigned on July 14, 2009. Dr. Eppanapally graduated from Osmania Medical College NTR UHS in 2002. Dr. Eppanapally holds California license A 106645.

Dr. Eppanapally's primary practice is Northeast Dialysis, at 5030 Office Park Dr, Bakersfield, CA 93309 in Kern County. The practice phone is (661) 872-3580.

Dr. Eppanapally's primary practice is Northeast Dialysis in Bakersfield, California. Dr. Eppanapally is also affiliated with Adventist Health Bakersfield. The medical group on file is Kern Medical. Dmand AI also links Dr. Eppanapally to 1 more hospital and 2 dialysis centers, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Eppanapally practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Eppanapally's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Eppanapally is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Eppanapally's licenses on file in 3 states: California, Connecticut and Massachusetts.

Dmand AI lists acute kidney failure, chronic kidney disease and hypercalcemia among the conditions Dr. Eppanapally treats.

CMS data shows 333 Medicare services from Dr. Eppanapally across 6 procedure codes in 2024, for 148 Medicare patients. Medicare paid $25,225 for them.

CMS counts 148 Medicare patients who saw Dr. Eppanapally in 2024. The largest group is 65 to 74, with 63 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 78% are also on Medicaid. Their average risk score is 3.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Eppanapally's median patient age at 61, with 51% women.

In 2024, Dr. Eppanapally wrote 412 Medicare Part D claims for 63 patients. 90% of them were for generic drugs. CMS names the drug for 286 of them, across 13 drugs with 11 or more claims each, at $21,003 in total drug cost. In 2023, CMS named 236 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Eppanapally for performance year 2024, reported as part of a group. Dr. Eppanapally accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Eppanapally as offering telehealth.

Dmand AI links 5 papers to Dr. Eppanapally, published from 2021 to 2024. Dr. Eppanapally has published most often in J Investig Med High Impact Case Rep. Dr. Eppanapally's most frequent co-authors are Ayham Aboeed, MD, Tushar Bajaj, MD and Janpreet Singh Bhandohal, MD.

CMS Open Payments shows 116 general payments to Dr. Eppanapally from 31 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 88% of the total. Astellas Pharma US Inc paid the most, $430.

Dr. Eppanapally graduated from Osmania Medical College NTR UHS in 2002.

Dr. Eppanapally is in network with 4 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and Regence Health Plans. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.